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Abstract
Background: Computerized decision support systems (CDSSs) are computer programs that provide doctors with
person-specific, actionable recommendations, or management options that are intelligently filtered or presented at
appropriate times to enhance health care. CDSSs might be integrated with patient electronic health records (EHRs)
and evidence-based knowledge.
Methods/Design: The Computerized DEcision Support in ONCOlogy (ONCO-CODES) trial is a pragmatic, parallel
group, randomized controlled study with 1:1 allocation ratio. The trial is designed to evaluate the effectiveness on
clinical practice and quality of care of a multi-specialty collection of patient-specific reminders generated by a CDSS
in the IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) hospital. We hypothesize that
the intervention can increase clinician adherence to guidelines and, eventually, improve the quality of care offered
to cancer patients. The primary outcome is the rate at which the issues reported by the reminders are resolved,
aggregating specialty and primary care reminders. We will include all the patients admitted to hospital services.
All analyses will follow the intention-to-treat principle.
Discussion: The results of our study will contribute to the current understanding of the effectiveness of CDSSs in
cancer hospitals, thereby informing healthcare policy about the potential role of CDSS use. Furthermore, the study
will inform whether CDSS may facilitate the integration of primary care in cancer settings, known to be usually
limited. The increasing use of and familiarity with advanced technology among new generations of physicians may
support integrated approaches to be tested in pragmatic studies determining the optimal interface between primary
and oncology care.
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Background
Background and rationale
Most hospitals collect huge amounts of electronic ad-
ministrative and clinical data. Without returning these
data to clinicians, collected e-information about health-
care services fails to inform clinicians [1]. Administrative
and demographic information, diagnoses, treatments,
prescription drugs, laboratory tests, hospitalizations, and
patient insurances, are cumulated. Doctors are primarily
involved in the collection of clinical data. Despite doc-
tors invest energies and time collecting patient informa-
tion during visits, this information, at best, comes back
after some times (e.g., at the end of the year), in a report
aggregating data from different patients and doctors. So,
the feedback is not pertinent to a specific patient (i.e.,
non-selective) but applies to an average patient visited in
the past (i.e. asynchronous) being not that helpful [2].
Computer applications that regularly and effortlessly
track key clinical and administrative data and select the
information that applies to a single patient may support
real-time clinical decision-making conveying on time
messages.
One of the major innovations in this field is computeri-
zed decision support systems (CDSSs) that are fully
integrated with electronic health records (EHRs) and
evidence-based knowledge [3]. CDSSs are information
technology-based software that provides clinicians, staff,
patients, or other individuals with person-specific, action-
able recommendations, or management options that are
intelligently filtered or presented at appropriate times to
enhance health and health care [4, 5].
Current research investigates CDSSs’ potential to assist
with problems raised in clinical practice, decrease the
rate of medication errors, increase the adherence of
clinicians to guideline- or protocol-based care, and,
ultimately, to improve the overall efficiency and quality
of healthcare delivery systems [6–19].
Few randomized controlled trials (RCTs) have evaluated
the impact of CDSSs on health care [5]. Most CDSSs sup-
ported few specific clinical decisions restricted to special-
ized care (e.g., vital parameter monitoring and critical care
in intensive care units).
The opportunity to improve patient care, by making
medical knowledge readily available to physicians at the
point of care, represents one of the main incentives for
investing on development and evaluation of these
sophisticated information systems.
Despite evidence shows that primary care helps
prevent illness and death, regardless of whether the care
is supplied in primary or secondary care settings, there
is limited research on integrating primary and oncology
care [20, 21]. Cancer patients are often old, have comor-
bidities, and face long diseases and treatments. They
would benefit from greater supply of primary care when
cared for conditions other than primary [22]. Few CDSSs
commercially available are capable to support a wide
range of medical conditions and support decisions such
as drugs and diagnostic test ordering, encompassing
oncology, other specialties and primary care. These tools
can potentially support the provision of integrated
healthcare services by hospital doctors who are primarily
accountable for addressing specialty diseases (i.e., cancer)
and developing a continuum between primary and spe-
cialty care.
Objective
Our study aims to evaluate the effectiveness of patient-
specific, point-of-care reminders generated by the
Medilogy Decision Support System (MediDSS) [23] on
clinical practice and on the improvement of quality of
care in cancer patients. We hypothesize that the inter-
vention can increase clinician adherence to recommenda-
tions targeting decisions both in primary and secondary
settings. Adherence to international guidelines, eventually,
can improve the quality of care offered to cancer patients
and survivors.
Methods/Design
This protocol is reported in accordance with the
SPIRIT 2013 guidance for content of clinical trial
protocols [24, 25].
Trial design
The Computerized DEcision Support in ONCOlogy
(ONCO-CODES) trial is a pragmatic, parallel group,
randomized controlled study with 1:1 allocation ratio.
The flow diagram of the study can be found in Fig. 1.
Study setting
The study will involve the medical staff of the day hos-
pital service and of the oncologic medicine departments
of the IRST Istituto Scientifico Romagnolo per lo Studio
e la Cura dei Tumori IRCCS (thereafter indicated as
IRST), which is a research center specialized in
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innovative care in the oncologic field and operational
since 2007. The hospital is placed in the Emilia-
Romagna region, in Italy, has 36 bed places, and is the
hub of several “spoke” ambulatory services. The catch-
ment population of the whole network is about 1,130,000
people, while the high specialization level of the hospital
service attracts patients from all Northern Italy [26].
The IRST counts more than 4900 admissions per year.
In addition to the in-patient wards which admit 1600
patients per year, the day hospital service performs over
3300 admissions annually.
The IRST has a medical staff of 140 doctors for a total
of 500 health professionals. Since 2007, the hospital has
been electronically tracking all clinical and administra-
tive information through an EHR system based on the
“Cartella clinica oncologica” platform (developed by a
local software house, Log80) [27].
Eligibility criteria and recruitment
As a pragmatic clinical trial [28, 29], ONCO-CODES
seeks to investigate the effectiveness of the computerized
reminders in everyday clinical practice with diverse
patients and varying conditions. Thus, we will enroll all
patients admitted to the oncology in-patient depart-
ments and the day hospital services of the IRST during
the study period, without applying any exclusion criteria.
Intervention
We selected the Medilogy Decision Support System
(MediDSS) after a comparative assessment of available
editorial products using a predefined set of essential
criteria [30, 31]. MediDSS is a product by Medilogy, an
Italian developer of scientific software and medical tech-
nology. Medilogy translated and adapted Evidence-based
medicine electronic decision support (EBMeDS) [32], a
CDSS developed by Duodecim Medical Publications Ltd.,
a company owned by the Finnish Medical Society Duode-
cim. EBMeDS can be described as a set of rules (scripts)
based on EBM guidelines and applied to structured health
data. MediDSS further includes knowledge from Swedish,
Finnish, INteraction X-referencing (SFINX), a drug-drug
interaction database containing concise evidence-based
information about the harms and benefits of about 18,000
drug interactions and adverse events [33].
MediDSS may be used as stand-alone application or may
integrate structured patient data from EHR to generate
patient-specific reminders, therapeutic suggestions, and
diagnosis-specific links to full-text guidelines. Reminders
are automatically generated and displayed on the monitors
of clinicians when they open a patient’s EHR, enter a new
diagnosis, prescribe a drug, or when new laboratory test re-
sults are available. Reminders were formed using inter-
national evidence-based guidelines and subsequently
approved by an international panel of experts.
Our study will use international reminders (n = 262),
which cover a large number of health conditions across
specialties and are derived from the EBMeDS, and local
reminders (n = 39), a series of tailored messages designed
by the hospital staff. Moreover, the CDSS provides infor-
mation about more than 10,000 drug–drug interactions
or other drug-related problems, giving advice on how to
handle them [34]. For instance, in a diabetic patient, a
diagnosis of renal failure, or a laboratory result of cre-
atinine increase, can trigger an alert message to reduce
the drug dosage (e.g., cisplatin) based on the patient’s
glomerular filtration rate (GFR).There are also several
reminders that may help oncologists in the holistic care
of the patient. Examples are: starting and maintaining
bisphosphonate therapy when a myeloma or metastatic
cancer is in the patient’s diagnosis list; alert on platelets
monitoring in patients who have recently started treat-
ment with heparins.
The reminders system will be “activated” in the
EHR of patients allocated to the intervention group,
while the system will be “silenced” in the EHR of
those allocated to the control group. Since during
care of control group patients, the generated re-
minders will not be shown to the physicians, control
is the standard clinical practice without reminders in
use. However, the best evidence for usual care will be
available to the physicians at all times during the
trial, if the doctor wishes to actively search for clin-
ical practice guidelines or other information sources.
All participating physicians will be informed on the
availability and use of the MediDSS system.
Fig. 1 Trial flow chart
Moja et al. Implementation Science  (2016) 11:153 Page 3 of 11
Stepped wedge implementation
The intervention is a new technology: its integration in
the current hospital system requires the configuration and
customization of the software. To allow security controls
and successful implementation, the CDSS will be sequen-
tially rolled out to participants over a number of time pe-
riods. We anticipate that the number of periods will be
limited (i.e., two or three periods). Over an initial period,
all participants will receive the intervention. The order in
which participants will receive the intervention is not de-
termined at random, but will be determined by selecting
physicians prone to provide constructive feedback to the
implementation team. The RCT adopts a stepped wedge
implementation of the intervention, but not a stepped
wedge design [35]. Sequential roll-out of the intervention
will not be considered a pilot phase of the trial, but a part
of the whole RCT.
Selection and development of local reminders
In order to encourage the participation of the hospital
staff within the study, we invited hospital representatives
to assess the priority needs of the hospital wards. Fol-
lowing consultation, an IRST-specific set of reminders
has been implemented.
Due to the increasing costs for the national health sys-
tem of certain kinds of drugs, i.e., high-cost monoclonal
antibodies, the Italian Medicines Agency developed
managed entry agreements based on a risk-sharing
policy. According to it, innovative oncology drugs are
the subjects of risk-sharing schemes [36]. The agree-
ments require manufacturers to pay-back part of the
price of the drug for each patient who fails to respond to
the new treatment. Hospitals track patient eligibility and
monitor the use of drugs included in the financial
scheme and their outcomes. Evidence collection of treat-
ment completion or interruption owing to progression
or toxicity has to follow rigid scheme and timeline. The
hospital then applies to the national health system for
pay-back. Late request for risk sharing or inaccurate
monitoring of progression lead to partial losses in the re-
imbursement to the hospital, with negative financial im-
pact. To support efficient documentation of treatment
failures, a set of reminders was developed to optimize
the timing of clinical-instrumental evaluations in accord-
ance with the procedures provided by the risk-sharing
schedule.
The local hospital expert group identified the following
drugs as of special interest: abiraterone, afatinib, afliber-
cept, axitinib, azacitidine, bevacizumab, bortezomib,
bosutinib, cetuximab, crizotinib, dabrafenib, dasatinib,
decitabine, enzalutamide, eribulin, erlotinib, everolimus,
gefitinib, ipilimumab, lapatinib, lenalidomide, nilotinib,
ofatumumab, paclitaxel, panitumumab, pazopanib,
pemetrexed, pertuzumab, plerixafor, ponatinib, sorafenib,
sunitinib, temserolimus, trabectidine, trastuzumab, vemura-
fenib, vinflunina, and vismodegib. The IRST-specific set of
reminders was developed taking into consideration the con-
ditions that have to be met for drug full reimbursement, in-
cluding the schedule for the diagnostic and laboratory
analyses required from the Italian Medicines Agency to
monitor the drug’s efficacy and safety [37].
In case of changes or updates in the agreements, the
reminders will be modified accordingly, in order to
guarantee the CDSS reminders to be always up-to-date.
An example of an algorithm is provided in Table 1.
Figures 2 and 3 show a snapshot of the activation
button and of the actual reminders.
Qualitative integration
The implementation of the intervention is a key aspect
of this RCT: the results will be valid if physicians will
use MediDSS in their clinical activities. Healthcare ser-
vice studies on CDSSs, however, suggested that the mere
provision of such technology does not guarantee its up-
take. In fact, even if a CDSS is readily available within a
hospital, there is a strong tendency to ignore its recom-
mendations, not trusting the majority of its alerts [38].
Our RCT is informed by qualitative interviews aimed to
detect how the CDSS fits in into clinical practice by
diverse health professionals involved in oncology patient
care. The interviews are a part of a larger cross-sectional
study, which involves three Italian hospitals [39]. The
interviews will explore barriers and facilitators that may
hinder the use of a CDSS in specialty settings, including
technical (e.g., poor usability or knowledge of system),
individual (e.g., negative perception of CDSS or EBM,
lack of motivation), group or organizational (e.g., struc-
tural or administrative constraints), and cultural factors
(e.g., adverse social norms).
The qualitative assessment will inform the trial inter-
vention, enabling possible improvements in the integrity
of the intervention and associated compliance. We will
collect feedbacks about usability, possible errors, or inac-
curacies of the information and recommendations pro-
vided. We will offer the best possible solutions to
Table 1 Algorithm for the correct prescription and the
reimbursement by the national health system of a
monoclonal antibody
Bevacizumab, an anti-angiogenetic drug, can be prescribed as a first line
treatment for non-small cell lung cancer patients. The patients have to
be evaluated by imaging tests after the 3rd administration and before
the 4th [37]. When the disease progresses, the drug is considered to be
not effective: the treatment is discontinued and the hospital is reimbursed
for the first three administrations. When the treatment provides the desired
results, the hospital can continue and the national health system covers
all the costs. In any other case, i.e., the treatment is ineffective but the
patient’s evaluation is performed after the 4th administration or the
treatment is continued after progression, the hospital will pay for the
drugs and get no reimbursement.
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clinicians and hospital staff to overcome these problems,
modifying the CDSS software if required and possible.
We cannot anticipate the types and level of changes that
will be proposed to improve the technology. Physicians
will volunteer for interviews, so it is possible we will
likely to include disproportionately more of those with
strong feelings or requests about the system.
Study outcomes
Active reminders represent potential problems in patient
management: the fewer the number of active reminders
persisting in a patient’s EHR, the better the health care
provided. The primary endpoint is a process outcome,
i.e., the rate at which the issues reported by the re-
minders are resolved (resolution rates). Reminders will
be considered resolved when the doctor acts to remove
the cause that motivated the reminder. The primary ana-
lysis will consider all reminders, irrespective of disease.
The CDSS will identify updates or changes in the patient
status, and related reminders, by monitoring any
changes in the patient EHR.
Secondary outcomes will explore resolution rates for re-
minders’ subgroup types as well as clinical outcomes. They
are the resolution rates of (i) the reminders targeting pri-
mary care, (ii) the reminders targeting oncology care, (iii)
the reminders targeting drugs that are the subjects of risk-
sharing schemes, (iv) the reminders for venous thrombo-
embolism (VTE) prevention, (v) in-hospital morbidity for
VTE-related causes, (vi) VTE-related mortality, and (vii)
in-hospital all causes mortality. VTE condition is a well-
known problem in oncologic care, being a preventable yet
still neglected disease. Research has shown the use of
CDSSs to improve the assessment of patients’ risk for
VTE, facilitate appropriate administration of prophylaxis
interventions, and reduce the rate of symptomatic VTE in
hospitalized patients [40–43]. We are interested in explor-
ing the effectiveness of VTE reminders when they are
combined together with several other types of reminders.
We will also explore any difference between the interven-
tion and control groups regarding clinical characteristics,
such as the site of tumor, physician, and inpatient/out-
patient settings.
Fig. 2 Activation button
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Sample size
We calculated the sample size on the basis of the pri-
mary outcome. A previous systematic review assessing
the effects of computer reminders delivered to clinicians
at the point-of-care on healthcare processes and out-
comes found a median improvement of 4.2 % in process
adherence across all reported process outcomes [44].
Accordingly, assuming resolution rates of 5% in the
intervention group versus 2 % in the control group (due
to a possible group contamination), we calculated that a
sample of 1306 reminders will be necessary to detect the
difference between the two groups (power = 0.80; α =
0.05, two-sided; 1:1 allocation). Because estimates for
intracluster correlation are not available, we increased
the required sample size (by 10 %) to 1436 reminders to
account for clustering by patient.
Moreover, based on a prior study evaluating EBMeDS,
which recorded an average of 0.30 reminders per indi-
viduals triggered at baseline [45], we determined that a
total number of approximately 4800 patients (2400 per
group) need to be enrolled. This figure corresponds to a
recruitment period of about 12 months for the oncology
departments and the day hospital services of the IRST.
Allocation and blinding
Anonymous patient identification (ID) numbers in the
EHR system will be the unit of randomization. An
individual external to the study group will generate the
anonymous IDs using a formula based on patients’
unique fiscal code numbers.
We will randomly assign patients to either the control
or experimental group with a 1:1 allocation. We will
follow a computer-generated randomization schedule
stratified by gender and age (0–30, 31–60, 61–80,
and >80 years) using permuted blocks of random
sizes [46]. Patients will be randomized immediately
after the first launch of their EHR (entry of demo-
graphic data by physicians at hospital admission),
and the allocation will be maintained through succes-
sive admissions.
Patients and study investigators (i.e., researchers, statis-
ticians, information technology specialists, and hospital
Fig. 3 Reminder
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representatives) will be blinded to the allocation of partici-
pants. We will maintain the blinding up to the dataset dis-
closure. On the other hand, blinding of physicians is not
feasible due to the nature of the intervention: the phys-
ician will know that a patient has been allocated to the
intervention group if an automatic, patient-specific re-
minder is displayed on the screen.
Data collection
The data collection for this study will follow the standard
data collection procedures of the IRST. We will collect
demographic (i.e., gender, age) and administrative (i.e.,
anonymous patient ID, admission and discharge dates,
diagnoses the following data from the EHR archive on a
regular basis) data from the EHR archive on a daily basis.
Information on reminders, including all scripts that have
been activated in a patient’s record, will also be collected
daily, but during the night, so as not to disturb or slow
down the use of the patient EHR.
Statistical methods
For the primary outcome (i.e., resolution rates), the re-
minder will serve as the unit of analysis, and the patient
the clustering factor. The patient will be the unit of ana-
lysis for the secondary outcomes (i.e., length of stay and
in-hospital mortality). All analyses will follow the
intention-to-treat principle: patients will be analyzed in
the group to which they have been randomized. Descrip-
tive statistics will be presented as means ± standard
deviations (SD), medians and interquartile ranges (IQR),
or percentages when appropriate. We will compare
continuous variables using the Student’s t test when
normally distributed, and the non-parametric two-
sample Wilcoxon rank-sum (Mann-Whitney) test when
they are not normally distributed. We will compare
categorical variables using the chi-squared test or the
Fisher’s exact test, as appropriate. To model the resolution
rates of the reminders, we will run a random effects
logistic regression analysis, accounting for clustering
by patient [47].
For hypothesis testing, we will consider a probability
level of less than 0.05 as statistically significant. All
statistical tests will be two-sided. We will use the Stata
software to perform all statistical analyses (Stata Corp.,
College Station, TX, USA).
Data monitoring
Data monitoring will inform the ONCO-CODES trial
conduct, identifying the potential need for adjustments:
(I) Sample size recalculation: Because the sample size
calculation utilizes several assumptions, we will
analyze the first batch of data collected and adjust
the estimated sample size, if necessary, at the end of
the sequential roll-out of the intervention. The
12-month recruitment period may also be adjusted,
accordingly.
(II) Interim analysis: We will perform an interim
analysis on the primary endpoint after 50 % of the
patients have been randomized, after 50 % of the
expected events have occurred, or after 6 months of
the study’s initiation (the assumed half-life of the
trial), whichever occurs first. An independent
statistician that is blind to the patient allocation will
perform the analysis. This analysis will inform
whether the intervention has been proven for
efficacy (beyond reasonable doubt). We will
subsequently decide whether (or not) it is necessary
to modify the study or prematurely terminate it, if
necessary.
(III)End of trial: The end of trial will occur 30 days
after the randomization of the last EHR. We will
submit an end of trial notification and final report
to the competent Ethical Committee, the IRST,
and to the Sponsor.
Harms
We do not anticipate any harms (or other unintended
effects) to study participants. Intervention and control
groups will differ in the presence (intervention) or
absence (control) of automatic reminders displayed on
physicians’ monitors. Patients assigned to the control
group will receive usual care without the reminders.
Nevertheless, we will consult an External Advisory
Board in the event that the discontinuation of the study
becomes an option due to unforeseeable reasons.
Ethical and regulatory considerations
This study is conducted in accordance with the princi-
ples of the Declaration of Helsinki (October 2013) [48].
As the ONCO-CODES trial has a cluster design (several
reminders, the unit of analysis, may derive from the
same EHR, the unit of randomization), we followed the
Ottawa statement to identify research participants and
apply ethical and regulatory protections [49, 50]. The
intervention (electronic CDSS reminders) does not dir-
ectly target patients, but physicians who can be considered
as the participants of the study. The risks associated with
the participation of physicians in the ONCO-CODES trial
are negligible. Physicians will be fully informed about the
involvement of the IRST in the ONCO-CODES trial and
trained to use the intervention. Requiring the signed con-
sent of each physician is not feasible and will impact on
the validity and generalizability of study results. Some
have argued that healthcare professionals have an obliga-
tion to participate in health system or knowledge transla-
tion research [51, 52]. We consider that the waiver of
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signed consents will not adversely affect the rights or
welfare of the research participants.
The Ethical Committee of IRST IRCCS Area Vasta
Romagna approved the ONCO-CODES protocol.
Protocol amendments
Any changes to the research protocol that may impact on
the study conduct (e.g., changes in study design, eligibility
criteria, study outcomes, sample size, study procedures, or
significant administrative aspects) will require a formal
amendment of the protocol. We will communicate any
such amendments to the trial registry (ClinicalTrials.gov)
and notify the health authorities in accordance with the
Italian regulations. We will further seek the approval of the
Ethical Committee for any amendments to the protocol.
Confidentiality
The trial staff will ensure the maintenance of partici-
pants’ anonymity. The participants will be identified only
by their initials and anonymous patient ID number.
Depersonalized data will be extracted from the EHR. All
documents will be stored securely and accessible only by
the trial investigators and authorized personnel.
Clinical data collected during the study will only be ac-
cessible to the staff at IRST, thus complying with the
current medical practice of the hospitals. The trial investi-
gators external to the hospital (statistician, data manager,
information technology personnel, etc.) will not access to
any information at the patients level.
The ONCO-CODES trial will comply with the Italian
Data Protection Act, which requires data to be anony-
mized as soon as it is practical to do so [53].
Dissemination policy
The trial results will be posted on ClinicalTrial.gov as
well as published in an open access medical journal.
We will further disseminate the study results to the
health professionals of the IRST involved in the study.
Datasets will be made available for research purposes
upon request after the end of the study.
Discussion
The results of our study will contribute to the current
understanding of the effectiveness of CDSSs on cancer
hospitals, thereby informing healthcare policy about the
potential role of CDSS use in supporting integrated
approaches between primary and specialty care. The in-
creasing use of and familiarity with advanced technology
among new generations of physicians call for pragmatic
studies determining the optimal interface between pri-
mary and oncology care [54].
Another trial, named CODES trial (ClinicalTrials.gov:
NCT02577198), is actually active [55]. It implements the
same CDSS of the ONCO-CODES trial. However, its
focus is on general hospitals and internal medicine pa-
tients. Therefore, it prioritizes an accurate implementa-
tion of the full spectrum of international reminders,
covering multiple fields of knowledge and practice,
rather than focusing on the impact of local and inter-
national reminders on a specific target population, i.e.,
cancer patients.
Strengths and limitations
The ONCO-CODES trial has several strengths. First, in
questions of effectiveness, the randomized controlled
trial is the most appropriate research design. Second, we
introduced a parallel qualitative study to elucidate why
the CDSS does or does fit in clinical practice. The quali-
tative interviews will enable us to collect different
attitudes and feedback, exploring the maturity of the
technology. If the technology is not mature, it is likely
that the results will be inconclusive and there will be no
differences between the intervention and the control. It
is always difficult to identify a right time to conduct a
summative evaluation of a complex technology, but
CDSSs seem to have more rather than less promise. So,
the time is appropriate to pragmatically evaluate their
effectiveness in large scale trials, accepting the risk that
the technology under study has moved on by the time
the trial is completed.
We preferred a pragmatic design under conditions that
mimics the actual use of CDSSs in practice to increase
the generalizability of the results as well as allows a
more accurate estimation of the intervention’s true ef-
fectiveness. We must note the methodological limitation
that physicians will not be blinded to the treatment
allocation. When a patient-specific reminder is automat-
ically displayed on the monitors, the physician will know
that the particular patient belongs to the intervention
group. We are aware that the unit of allocation (i.e.,
patient) and the lack of physician blinding can lead to
possible group contamination: the doctors will be alter-
natively exposed to intervention and control group
patients, applying the knowledge from a reminder gener-
ated for a patient allocated to the intervention group to
a patient allocated to the control group. This possible
learning effect (contamination of knowledge) can
decrease the trial effect and lead to a more conservative
effect estimate (i.e., towards the null). Randomization at
the physician level, however, does not eliminate the pos-
sibility of contamination as physicians can care for pa-
tients across different wards; this level of randomization
would, moreover, increase the organizational complexity
of the study. A second factor that may decrease the trial
effect is the adoption of an intention-to-treat analysis:
not all physicians may adhere to the reminders within
the study. Noncompliance is problematic because it re-
sults in a smaller difference between the intervention
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and comparison groups than may exists, thereby diluting
the real impact of an intervention. Indeed, if the results
will be positive, we will be confident that the CDSS is
very likely to modify the resolution rates of the
reminders, since most design factors work to dilute the
effects.
Conclusion
This is a pragmatic trial that is powered to find small
(but important) effects of a CDSS on process outcomes.
While a trial to assess true clinical endpoints would be
ideal, the size and timeframe of such a trial would chal-
lenge its feasibility. Positive results in terms of improved
adherence to reminders indicates that the CDSS inter-
vention tested in this trial should help specialty physi-
cians to close the gap between their intended and actual
behaviors with respect to the primary and secondary
care they provide for their patients. If the intervention
works only in one setting (e.g., specialty care), it could
be further tested trying more intensive approaches to
facilitate interoperable EHR accessible to patients and
health professionals at multiple facilities.
Trial status
The implementation phase of the study was completed
in October 2015, when the CDSS (MediDSS) was fully
integrated with the hospital’s EHR (Cartella clinica onco-
logica). Subject recruitment and data collection began in
November 2015 in the IRST hospital.
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